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2014. For 542 surgical procedures during the study period, 62 SSI (11.4%)
occurred as compared to 102 cases for 680 in the control period (15%). The
adjusted odds ratio of the SSI rate was 0.7319 and was found to be 27%
lower post intervention.
Conclusion: The implementation of the bundle was associated with
improved compliance over time and a significant reduction of the SSI
rate. This makes the bundle an important tool to improve patient
safety.
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Introduction: Direct hemoperfusion with polymyxin-B has been reported to
improve hemodynamics in postsurgical patients. In 2012, the Japanese
Guidelines for the Management of Sepsis were published and mention the
efficacy of polymyxin-B direct hemoperfusion. But how to use and the target
patients are varied by facilities. We investigated the effective use of
polymyxin-B direct hemoperfusion in nonsurgical patients.
Methods: We analyzed retrospectively all septic shock patients who were
treated with polymyxin-B hemoperfusion between January 2008 and
December 2012.We checked their mean arterial pressure (MAP), and
vasopressor requirement every 30 minutes until stopping treatment.
Results: There were 32 patients under treatment and 11 patients did not
need surgical treatment. Even in the nonsurgical group, hemodynamic
states and vasopressor requirement was improved after polymyxin-B
hemoperfusion started. And the effects were continued over 120 minutes. A
second plolymyxin-B hemoperfusion treatment underwent in nine patients.
In second treatment, MAP increased in the nonsurgical group greater than
in the postsurgical group.
Conclusion: Polymyxyn-B direct hemoperfusion improves hemodynamic
status even in nonsurgical patients. A second polymyxin-B direct
hemoperfusion is effective especially in nonsurgical septic shock patients.
And if its hemodynamic effect was significantly, long-time treatment
should be considered.
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Introduction: Efficient fight with infection requires robust production of
immunocompetent cells. This response is called emergency hematopoiesis
and depends on the proliferation of progenitor cells and awakening
dormant hematopoietic stem cells (HSCs) into cycling. As during sepsis
an altered immune system is often observed, it seems important to
reveal the impact of this syndrome on HSCs. Recent discoveries have
shown that HSCs circulate in the peripheral blood and may boost local
immune response via paracrine mechanisms and differentiation into
myeloid cells. Altogether, these rationales led us to investigate the
circulating HSCs in septic patients and in the bone marrow (BM) of septic
‘humanized mice’ transplanted earlier with human HSCs.
Methods: Samples of peripheral blood were collected from 23 patients with
sepsis (on days 1 and 3) and 20 healthy volunteers. The following antigens
were analyzed by flow cytometry: CD34, CD38, Ki-67, CD133, Lin and CD45.
In order to investigate HSCs in their microenvironment, a model of cecum
ligation and puncture (CLP) was performed on the NOD.Cg-Prkdc/scidIL2rg
mice that were transplanted with human cord blood CD34+ cells 8 weeks
earlier. BM cells were analyzed 24 hours after CLP by colony-forming unit
assay with medium supporting growth of human cells.
Results: Septic patients had a significantly increased (threefold, P < 0.01)
number of CD34+CD38- HSCs on the third day of the disease. Also, the
CD133+ HSC number was increased in septic patients, while CD34+CD45
+Lin- progenitors were detected at much lower level than in controls.
Interestingly, Ki-67+CD34+Lin- cells were fourfold higher in septic patients.
Patients with higher number of CD133+ HSCs had significantly lower
likelihood of 60-day survival (P < 0.05). Analysis of human HSCs from BM
of septic mice revealed significantly compromised hematopoietic colonies
output (248 vs. 125 in sham animals). CLP caused also expansion of
CD34+CD38- HSCs in BM and absolute increase of Ki-67+CD34+Lin- cells
(1.5-fold).
Conclusion: In this work we have observed significant changes in
circulating HSCs during sepsis. During the disease, dormant HSCs enter the
cell cycle (measured by Ki-67 expression) and are mobilized to the
peripheral blood. However, the progenitor cells disappear from circulation.
Novel use of humanized mice confirmed expansion of early human HSCs in
BM during the sepsis model. Despite expansion of the HSC pool, the
amount of functional progenitors in BM is decreased in this model. We
suggest that HSCs play a significant role in the course of sepsis and may
become a new prognostic and therapeutic target.
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Introduction: Fluid bolus therapy (FBT) is a ubiquitous intervention in
intensive care. However, the physiological effects in the critically ill are
poorly understood. Therefore, we systematically reviewed the contemporary
literature to determine the current practice and effect of FBT in the
management of severe sepsis and septic shock.
Methods: We interrogated the MEDLINE, CENTRAL and EMBASE electronic
reference databases using a combination of terms to define a set of records
of studies of fluid administration in patients with severe sepsis or septic
shock. To achieve contemporary relevance, results were limited to English-
language studies in adults between 2010 and 2013.
Results: We identified 22 prospective observational studies, four
retrospective observational studies, two quasi-experimental studies, and five
randomised controlled trials (RCTs), 41 boluses in total. No RCT compared
FBT with alternative interventions. The median fluid bolus was 500 ml
(range: 100 to 1,000 ml) administered over 30 minutes (range: 10 to
60 minutes) and 0.9% sodium chloride solution was the most commonly
administered. Although 17 studies describe the temporal course of
physiological changes after FBT in 31 patient groups, only three studies
describe the physiological changes at 60 minutes, and only one study
beyond this point (Figure 1). No studies related the physiological changes
after FBT with clinically relevant outcomes.
Conclusion: There is a need for obtaining randomised controlled evidence
for the physiological effects of FBT in patients with severe sepsis and septic
shock beyond the period immediately following its administration.
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Introduction: Patients are frequently rehospitalized in the 90 days after
severe sepsis. The rate of readmission exceeds patients’ baseline rate of
hospitalization, and also exceeds the rate after matched nonsepsis
hospitalizations [1]. We sought to determine the most common readmission
diagnoses after severe sepsis, the extent to which readmissions may be
preventable, and whether the pattern of readmission diagnoses differs from
that of nonsepsis hospitalizations.
Methods: We studied participants in the US Health and Retirement Study
with linked Medicare claims (1998 to 2010) [2]. Using validated methods
[3,4], we identified severe sepsis and nonsepsis hospitalizations, then
measured 90-day readmissions in each cohort. Using Healthcare Cost &
Utilization Project’s Clinical Classification Software [5], we determined the
10 most common readmission diagnoses after severe sepsis. We measured
rates of ‘potentially preventable’ readmissions using published definitions
[6]. We compared rates of all-cause, potentially preventable, and cause-
specific hospitalizations between survivors of severe sepsis and nonsepsis
hospitalizations using chi-squared tests.
Results: We identified 3,703 severe sepsis and 44,840 nonsepsis
hospitalizations, of which 3,036 (82.0%) and 43,539 (93.1%) survived to
discharge, respectively. In the next 90 days, 43.6% of severe sepsis
survivors were rehospitalized, compared to 34.8% of nonsepsis survivors,
P < 0.001. The top readmission diagnoses following severe sepsis (Table 1)
included several recognized potentially preventable diagnoses: heart
failure, pneumonia, exacerbation of chronic obstructive pulmonary disease
(COPD), and urinary infection. Also common were readmissions for sepsis,
acute renal failure, and aspiration pneumonitis, diagnoses that could
plausibly be prevented or treated early to prevent hospitalization. Patterns
of readmission differed in severe sepsis survivors; rates of readmission for
sepsis, renal failure, respiratory failure, device complication, and aspiration
pneumonitis were higher and accounted for a greater proportion of the
total readmissions. Potentially preventable hospitalizations - infection
(sepsis, pneumonia, urinary tract, and skin or soft tissue), heart failure,
COPD exacerbation, acute renal failure, and aspiration pneumonitis -
accounted for 40.5% of all readmissions after severe sepsis (compared to
25.8% following nonsepsis admission, P < 0.001), and 19.6% of severe
sepsis survivors experienced a readmission for one of these diagnoses
(compared to 9.5% following a nonsepsis admission, P < 0.001).
Conclusion: Forty percent of hospitalizations after severe sepsis occur for
diagnoses that may be preventable. A few disease categories account for
a relatively large proportion of the hospitalizations after severe sepsis,
suggesting the feasibility of tailoring postdischarge interventions to
patient’s personalized risk for these common postsepsis diagnoses.
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Figure 1(abstract P34) Haemodynamic changes following FBT at 1, 2, 3 and 4 hours
Table 1(abstract P35) Top ten hospitalization diagnoses in the 90 days following severe sepsis
Rank Diagnosis category Proportion of all 90-day admissions (%) Survivors with 90-day admission (%)
1 Congestive heart failure, nonhypertensive 10.4 5.7*
2 Septicemia 9.5* 6.5*
3 Pneumonia 5.4 3.5*
4 Rehabilitation care 5.1 3.2
5 Acute and unspecified renal failure 4.6* 3.2*
6 Respiratory failure 4.1* 2.5*
7 Complication of device, implant, or graft 3.5* 2.3*
8 COPD and bronchiectasis 3.1 1.8
9 Urinary tract infection 3.1 1.8*
10 Aspiration pneumonitis 2.8* 1.8*
*Value greater than that of nonsepsis survivors, P ≤ 0.001 for each comparison
Critical Care 2014, Volume 18 Suppl 2
http://ccforum.com/supplements/18/S2
Page 24 of 53
